Impact of Prior Hepatitis C Infection on Post-transplant Outcomes in Deceased Donor Kidney Recipients: A Real-world Retrospective Observational Study in the Era of Directly Acting Antivirals
Indian Journal of Kidney Diseases · 2026-07 · 5 (3) · 163-169
DOI: 10.4103/ijkd.ijkd_25_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Kidney Diseases, online erschienen am 29.09.2026. Verfasst von K. Ganapathy Raja und 4 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A BSTRACT Background: Management of Hepatitis C virus (HCV)infection with Directly -acting antiviral drugs (DAAs) has drastically improved the chances of sustained virologic remission(SVR) and kidney transplantation in HCV-infected patients. However residual immunologic and hepatic sequelae may persist post-SVR, potentially influencing infection risk, rejection rates and graft survival. This study compares outcomes of HCV positive positive-transplant recipients with HCV negative-transplant recipients in the present era of DAAs. Materials and Methods: This retrospective cohort study included 102 deceased donor renal transplant recipients categorized into two groups: HCV-positive ( N = 40) patients and HCV-negative ( N = 62) patients. HCV-positive patients received DAAs and achieved SVR prior to transplant. Baseline characteristics, incidence and time of post-transplant complications, graft and patient survival, and causes of death were compared.
Results
The HCV positive patients exhibited significantly higher incidences of pneumonia (35.0% vs. 9.7%, P = 0.002), tuberculosis (35.0% vs. 9.8%, P = 0.002), BK virus infection (15.0% vs. 1.6%, P = 0.014), acute rejection (47.5% vs. 21.0%, P = 0.005), chronic rejection (40.0% vs. 21.0%, P = 0.037), and liver dysfunction (27.5% vs. 6.7%, P = 0.004). Posttransplant urinary tract infection occurred significantly earlier in HCV positive patients (median 57 days vs. 95 days, P = 0.022). Importantly, death-censored survival was significantly shorter in HCV positive patients (mean 2289.2 days vs. 3547.5 days, P = 0.005). Infection was the leading cause of death in both groups, however higher in HCV positive patients (64.7% vs. 50.0%).
Conclusion
The study showed poor outcomes of kidney transplantation in HCV positive recipients compared to HCV negative recipients despite the advances in its treatment.
Zitieren
APA
Raja, K. G., Sebastin, R., Rajendran, M., Balamurugan, S., & Durai, R. (2026). Impact of Prior Hepatitis C Infection on Post-transplant Outcomes in Deceased Donor Kidney Recipients: A Real-world Retrospective Observational Study in the Era of Directly Acting Antivirals. Indian Journal of Kidney Diseases, 5(3), 163-169. https://doi.org/10.4103/ijkd.ijkd_25_26
Vancouver
Raja KG, Sebastin R, Rajendran M, Balamurugan S, Durai R. Impact of Prior Hepatitis C Infection on Post-transplant Outcomes in Deceased Donor Kidney Recipients: A Real-world Retrospective Observational Study in the Era of Directly Acting Antivirals. Indian Journal of Kidney Diseases. 2026;5(3):163-169. doi:10.4103/ijkd.ijkd_25_26
BibTeX
@article{Raja2026,
author = {Raja, K. Ganapathy and Sebastin, Rakesh and Rajendran, Manorajan and Balamurugan, S. and Durai, Rakesh},
title = {Impact of Prior Hepatitis C Infection on Post-transplant Outcomes in Deceased Donor Kidney Recipients: A Real-world Retrospective Observational Study in the Era of Directly Acting Antivirals},
journal = {Indian Journal of Kidney Diseases},
year = {2026},
volume = {5},
number = {3},
pages = {163--169},
doi = {10.4103/ijkd.ijkd_25_26}
}
EUVIMED